Cyberonics to carry on without CCO after James Reinstein resigns
This article was originally published in Clinica
James Reinstein has resigned as Cyberonics' senior vice-president and chief commercial officer due to personal reasons, and the vagal nerve stimulation specialist has decided not to replace him. Mr Reinstein will leave the company on 27 April 2012, at the end of its current fiscal year; until then he will help transfer his responsibilities to other Cyberonics' employees. This includes Mark Verratti, who was recently appointed vice-president of sales in the Americas, Asia and EMMEA (Eastern Mediterranean, Middle East and Africa), and will continue in this role.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.